{
    "ticker": "ALDX",
    "name": "Aldeyra Therapeutics, Inc.",
    "description": "Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of immune-mediated diseases and conditions. Founded in 2011 and headquartered in Lexington, Massachusetts, Aldeyra aims to address significant unmet medical needs through its novel drug candidates. The company is particularly noted for its work in the field of ocular diseases, with its lead product candidate, reproxalap, designed to treat dry eye disease and allergic conjunctivitis. Aldeyra\u2019s approach to drug development leverages its expertise in the modulation of the immune system and aims to provide safer and more effective therapeutic options. The company is also exploring treatments for other immune-mediated conditions, including certain forms of non-infectious anterior uveitis and other diseases characterized by dysregulated immune responses. Aldeyra is committed to advancing its pipeline through rigorous clinical trials and regulatory processes, with a focus on delivering meaningful improvements in patient outcomes. Its mission is to enhance the quality of life for patients suffering from these debilitating conditions through cutting-edge science and a commitment to innovation in therapeutic development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2011",
    "website": "https://www.aldeyra.com",
    "ceo": "Todd C. Brady",
    "social_media": {
        "twitter": "https://twitter.com/AldeyraTx",
        "linkedin": "https://www.linkedin.com/company/aldeyra-therapeutics/"
    },
    "investor_relations": "https://ir.aldeyra.com",
    "key_executives": [
        {
            "name": "Todd C. Brady",
            "position": "CEO"
        },
        {
            "name": "Michael L. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ocular Therapies",
            "products": [
                "Reproxalap"
            ]
        },
        {
            "category": "Immune-Mediated Disease Treatments",
            "products": []
        }
    ],
    "seo": {
        "meta_title": "Aldeyra Therapeutics, Inc. | Innovative Ocular and Immune-Mediated Disease Treatments",
        "meta_description": "Learn about Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing innovative therapies for immune-mediated diseases and ocular conditions.",
        "keywords": [
            "Aldeyra",
            "Biotechnology",
            "Reproxalap",
            "Ocular Therapies",
            "Immune-Mediated Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Aldeyra Therapeutics known for?",
            "answer": "Aldeyra Therapeutics is known for developing innovative therapies for immune-mediated diseases and ocular conditions."
        },
        {
            "question": "Who is the CEO of Aldeyra Therapeutics?",
            "answer": "Todd C. Brady is the CEO of Aldeyra Therapeutics, Inc."
        },
        {
            "question": "Where is Aldeyra headquartered?",
            "answer": "Aldeyra is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What is Aldeyra's lead product candidate?",
            "answer": "Aldeyra's lead product candidate is reproxalap, aimed at treating dry eye disease and allergic conjunctivitis."
        },
        {
            "question": "When was Aldeyra founded?",
            "answer": "Aldeyra was founded in 2011."
        }
    ],
    "competitors": [
        "AVXL",
        "SAGE",
        "SRNE",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}